Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 10/20 | 0.77 |
| ▸ | PIEZO1 | Q92508 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2524258 | 0.87 | TERT (0.77) | TERTPIEZO1RAB9AMEN1KMT2A | |
| SCHEMBL6490578 | 0.81 | PIEZO1 (1.00) | TERTPIEZO1MEN1KMT2ALMNA | |
| SCHEMBL6489665 | 0.80 | MEN1 (0.60) | TERTRAB9AMEN1KMT2AGSK3B | |
| SCHEMBL6492979 | 0.78 | MEN1 (0.59) | TERTRAB9AMEN1KMT2AGSK3B | |
| SCHEMBL23195706 | 0.77 | PIEZO1 (0.81) | TERTPIEZO1MEN1KMT2ALMNA | |
| SCHEMBL23195699 | 0.76 | PIEZO1 (0.78) | TERTPIEZO1MEN1KMT2ALMNA | |
| SCHEMBL3263155 | 0.75 | LMNA (0.72) | RAB9AMEN1KMT2ALMNAHPGD | |
| SCHEMBL23195760 | 0.75 | PIEZO1 (0.74) | TERTPIEZO1MEN1KMT2ALMNA | |
| SCHEMBL23195361 | 0.75 | PIEZO1 (0.83) | TERTPIEZO1RAB9ALMNAHPGD | |
| SCHEMBL27952107 | 0.75 | TERT (0.74) | TERTPIEZO1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6894054-B2 | Heterocyclic inhibitors of glycine transporter 2 | TELIK, INC. (US) | 2005-05-17 | — | — | US | claimed |
| EP-1357913-A1 | HETEROCYCLIC INHIBITORS OF GLYCINE TRANSPORTER 2 | TELIK, INC. (US) | 2003-11-05 | — | — | EP | claimed |
| US-20030073726-A1 | Heterocyclic inhibitors of glycine transporter 2 | TELIK, INC. | 2003-04-17 | — | — | US | claimed |
| WO-2002064135-A1 | HETEROCYCLIC INHIBITORS OF GLYCINE TRANSPORTER 2 | TELIK, INC. (US) | 2002-08-22 | — | — | WO | claimed |
| US-6894054-B2 | Heterocyclic inhibitors of glycine transporter 2 | TELIK, INC. (US) | 2005-05-17 | — | — | US | disclosed |
| EP-1357913-A1 | HETEROCYCLIC INHIBITORS OF GLYCINE TRANSPORTER 2 | TELIK, INC. (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20030073726-A1 | Heterocyclic inhibitors of glycine transporter 2 | TELIK, INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2002064135-A1 | HETEROCYCLIC INHIBITORS OF GLYCINE TRANSPORTER 2 | TELIK, INC. (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073726-A1 | Heterocyclic inhibitors of glycine transporter 2 | SLC1A2, SLC1A1, SLC1A3 | TERT 4471/4885PIEZO1 2298/4885RAB9A 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.